Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 7/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31067701 | 1.00 | KLKB1 (0.39) | KLKB1MAOAMAOBKDM4EMEN1 | |
| SCHEMBL18604654 | 0.77 | MAOA (0.44) | MAOAMAOBKDM4EMAPTTDP1 | |
| SCHEMBL28883135 | 0.77 | MAOA (0.44) | MAOAMAOBKDM4EMEN1LMNA | |
| SCHEMBL29825453 | 0.77 | MAOA (0.44) | MAOAMAOBKDM4EMAPTTDP1 | |
| SCHEMBL17064932 | 0.76 | ACHE (0.45) | KDM4EMEN1LMNAMAPTKMT2A | |
| SCHEMBL1466819 | 0.73 | MAOA (0.47) | MAOAMAOBKDM4EMAPTTDP1 | |
| SCHEMBL30446809 | 0.70 | HRH1 (0.40) | KLKB1MAOAMAOBKDM4EMEN1 | |
| SCHEMBL17064662 | 0.70 | HRH1 (0.40) | KLKB1MAOAMAOBKDM4EMEN1 | |
| SCHEMBL24054852 | 0.69 | TAAR1 (0.42) | CYP3A4CASP1RECQLOPRM1OPRD1 | |
| SCHEMBL4667347 | 0.69 | ALDH1A1 (0.38) | MAOAKDM4EMAPTGFERTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4663636-A2 | TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-28 | — | — | US | disclosed |
| US-20250257040-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-14 | — | — | US | disclosed |
| EP-4180424-B1 | SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2025-06-25 | — | — | EP | disclosed |
| US-12162838-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-12116346-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| CN-113307772-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20240150295-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-05-09 | — | — | US | disclosed |
| US-20240150296-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-05-09 | — | — | US | disclosed |
| US-11708333-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20190322626-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2019-10-24 | — | — | US | disclosed |
| US-20190322626-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2019-10-24 | — | — | US | disclosed |
| US-10329260-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-10329260-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180354906-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-12-13 | — | — | US | disclosed |
| US-10125102-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180258049-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-09-13 | — | — | US | disclosed |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-03-16 | — | — | US | disclosed |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-03-16 | — | — | US | disclosed |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180354906-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | KLKB1 1/4885MAOA 703/4885MAOB 621/4885 |
| US-12116346-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KLKB1 1/4885MAOA 598/4885MAOB 588/4885 |
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KLKB1 1/4885MAOA 598/4885MAOB 588/4885 |
| US-20240150296-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KLKB1 1/4885MAOA 598/4885MAOB 588/4885 |
| US-10329260-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885MAOA 703/4885MAOB 621/4885 |
| US-10125102-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885MAOA 703/4885MAOB 621/4885 |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | KLKB1 1/4885MAOA 703/4885MAOB 621/4885 |
| US-20190322626-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | KLKB1 1/4885MAOA 703/4885MAOB 621/4885 |
| US-20240150295-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KLKB1 1/4885MAOA 598/4885MAOB 588/4885 |
| US-20250257040-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KLKB1 1/4885MAOA 598/4885MAOB 588/4885 |
| US-11708333-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885MAOA 984/4885MAOB 887/4885 |
| US-20180258049-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | KLKB1 1/4885MAOA 703/4885MAOB 621/4885 |
| US-12162838-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KLKB1 1/4885MAOA 598/4885MAOB 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.